Michele Park, PhD, is a Partner at New Enterprise Associates (NEA) on the firm’s Healthcare team. See sector focus and contact routes.
Michele Park, PhD, is a Partner at New Enterprise Associates (NEA) on the firm’s Healthcare team, where she focuses specifically on biopharma investments. She joined NEA in 2021 after previously leading the launch of the Clarus Cancer Fund at Clarus Ventures and working as a biotechnology research analyst at Credit Suisse and Piper Jaffray. NEA invests across Seed, Series A, and Series B+ stages with check sizes ranging from $500,000 to $50 million, though Park’s specific lead or follow behavior is not publicly detailed. One notable portfolio company she has invested in is Tagworks Pharmaceuticals, which she backed at the Series A stage. Park holds a PhD in molecular biology from Weill Cornell and a BA from Princeton, and she serves as Co-Chair of the CPRIT Product Development Advisory Committee. While she has no widely published public writing cited in available sources, her distinctive point of view includes pioneering an investment model at Clarus that generated returns while fueling cancer research through donations.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in San Francisco when building a target list.
Investors like Michele Park · Full investor directory · Investor access · Company funding database